27 May

Emerging Markets: Medtronic’s Key Revenue Driver in 2019

WRITTEN BY Margaret Patrick

Revenue performance by geography

In the fourth quarter, Medtronic (MDT) earned revenue of $4.28 billion in the US market, a YoY (year-over-year) rise of 2.3% on a reported and constant-currency basis. The company earned revenue of $2.58 billion from non-US developed markets, a YoY fall of 5.3% on a reported basis but a 1.7% rise on a constant-currency basis.

In the fourth quarter, emerging markets contributed $1.29 billion worth of Medtronic’s revenue, YoY rises of 3.9% on a reported basis and 12.0% on a constant-currency basis. According to its fourth-quarter earnings conference call, this performance was driven by YoY revenue growth of 13% in China, 22% in South Asia, 20% in Southeast Asia, 13% in the Middle East and Africa, and 8% in East Africa and Latin America. Medtronic has managed to attain these robust growth rates based on strategies such as public and private partnerships, a strong distribution channel, and the localization of manufacturing and research and development activities.

Emerging Markets: Medtronic’s Key Revenue Driver in 2019

In the fourth quarter, US, non-US developed, and emerging markets accounted for 52%, 32%, and 16% of Medtronic’s total revenue, respectively.

Fiscal 2019 performance

In fiscal 2019, Medtronic earned revenue of $16.19 billion from the US market, a YoY rise of 2.0% on a reported basis and a rise of 4.7% on a constant-currency basis. The company earned revenue of $9.63 billion from non-US developed markets, a flat YoY performance on a reported basis and a 3.4% rise on a constant-currency basis. Emerging markets contributed $4.73 billion worth of Medtronic’s revenue, YoY rises of 6.3% on a reported basis and 12.7% on a constant-currency basis.

In fiscal 2019, US, non-US developed, and emerging markets accounted for 53%, 32%, and 15% of Medtronic’s total revenue, respectively.

In fiscal 2019, the restorative therapies group, minimally invasive therapies group, cardiac and vascular group, and diabetes group accounted for 27%, 28%, 37%, and 8% of Medtronic’s total revenue, respectively.

The restorative therapies group reported revenue of $8.18 billion in fiscal 2019, reflecting YoY rises of 5.7% on a reported basis and 6.6% on a constant-currency basis. The cardiac and vascular group reported revenue of $11.51 billion, reflecting YoY rises of 1.3% on a reported basis and 2.9% on a constant-currency basis. The minimally invasive therapies group reported revenue of $8.48 billion, a YoY fall of 2.7% on a reported basis but a rise of 5.8% on a constant-currency basis. Finally, the diabetes group reported revenue of $2.39 billion in fiscal 2019, reflecting YoY rises of 11.7% on a reported basis and 13.4% on a constant-currency basis.

Latest articles

Currently, 33 states and Washington, D.C., have legalized medical cannabis, but it's illegal in Kansas. Even having a small amount is considered a crime.

On November 8, Arkansas joined the other eight states that support the DOJ's decision to approve the proposed T-Mobile (TMUS) and Sprint (S) merger deal.

One thing about Tesla's China Gigafactory that's surprised bulls and bears alike is the impressive progress the facility has made.

Nvidia plans to announce its earnings for Q3 of fiscal 2020 on November 14 after the bell. Analysts expect its revenue to fall 8.2% YoY to $2.92 billion.

In the week that ended on November 8, WTI crude oil prices rose 1.9% and closed at $57.24 per barrel. However, oversupply concerns limited the upside.

Today, Donald Trump tweeted a comment by JPMorgan Chase CEO Jamie Dimon suggesting Trump's China tariffs have hit the country hard.